Glucocorticoid News and Research

RSS

Glucocorticoid is a compound that belongs to the family of compounds called corticosteroids (steroids). Glucocorticoids affect metabolism and have anti-inflammatory and immunosuppressive effects. They may be naturally produced (hormones) or synthetic (drugs).

Miscarriage and molecular signals: an interview with Prof Brosens and Prof Quenby

Miscarriage is defined as the spontaneous loss of pregnancy before the baby reaches viability. Besides the physical trauma, miscarriage causes considerable anxiety, stress, and depression.

17 Jan 2013

Osteoporosis screening: an interview with Professor Cyrus Cooper

Osteoporosis is defined as a reduction in bone mass coupled with micro-architectural deterioration of bone tissue which predisposes to fractures. Osteoporosis manifests through an increased risk of fracture, and age-related fractures are a major public health problem.

17 Dec 2012

FDA approves Novartis Signifor injection for treatment of Cushing's disease

Novartis announced today that the US Food and Drug Administration (FDA) has approved Signifor (pasireotide) injection for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative.

14 Dec 2012

New study could help develop anti-inflammatory drugs with fewer side effects

10 Dec 2012

Osteoporosis medication Aclasta now available on Canadian public drug plans

Osteoporosis Canada congratulates the Ontario government, the New Brunswick government, the Saskatchewan government and the British Columbia government for providing access to a new osteoporosis medication. Aclasta (zoledronic acid) is now available on public and private drug plans in Ontario, BC, SK, and NB meaning Canadians at high risk for fractures have access to increased treatment options.

23 Nov 2012

Janssen receives positive opinion from EMA CHMP for ZYTIGA to treat mCRPC

Janssen-Cilag International NV (Janssen) announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of the oral, once-daily medication ZYTIGA for use in combination with prednisone or prednisolone in the treatment of metastatic castration-resistant prostate cancer (mCRPC), in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated.

19 Nov 2012

Treatment-related heart failure risk for rheumatoid arthritis patients revealed

Rheumatoid arthritis patients have no greater risk for heart failure with tumor necrosis factor-alpha therapy than with nonbiologic disease-modifying antirheumatic drugs, research suggests.

19 Nov 2012

Receptor expression sheds light on nasal polyposis

The increased expression of a leukotriene receptor and a glucocorticoid receptor may contribute to the development of nasal polyposis, report researchers.

6 Nov 2012

GILZ protein encourages bone growth in mouse model

Georgia Health Sciences University researchers have developed a mouse that errs on the side of making bone rather than fat, which could eventually lead to better drugs to treat inflammatory diseases such as rheumatoid arthritis.

16 Oct 2012

Antibiotic proved to be Achilles’ heel for some

US clinicians have identified patients at particular risk for Achilles injury while using quinolones.

4 Oct 2012

Glucocorticoids can thwart androgen receptor activity and regulate fat storage

In the body's ongoing effort to maintain a healthy weight, an arsenal of cellular proteins called androgen receptors is critical for blocking fat accumulation. Now researchers reporting in the September issue of the Cell Press Journal Chemistry & Biology have discovered that naturally occurring steroids called glucocorticoids can thwart the receptors' activity, ultimately encouraging fat buildup.

21 Sep 2012

Top line results from Zalicus Synavive Phase 2b study in rheumatoid arthritis

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced top line results from its randomized, double-blind, placebo-controlled, Phase 2b clinical trial of Synavive in rheumatoid arthritis.

10 Sep 2012

Steroid induced Cushing’s warning

People who develop Cushing’s syndrome as a result of taking systemic glucocorticoids are at very high risk of cardiovascular disease, warn researchers.

8 Aug 2012

Cushing’s patients must be screened for heart disease

Individuals who use glucocorticoids and exhibit iatrogenic Cushing’s syndrome should be “aggressively” targeted for early screening of cardiovascular risk factors, say researchers.

7 Aug 2012

Risky prenatal use of steroid to prevent intersex, tomboys and lesbians

A new paper just published in the Journal of Bioethical Inquiry uses extensive Freedom of Information Act findings to detail an extremely troubling off-label medical intervention employed in the U.S. on pregnant women to intentionally engineer the development of their fetuses for sex normalization purposes.

3 Aug 2012

High maternal choline intake may reduce risk of hypertension and diabetes in babies

New research from Cornell University indicates that pregnant women who increase choline intake in the third trimester of pregnancy may reduce the risk of the baby developing metabolic and chronic stress-related diseases like high blood pressure and diabetes later in life.

2 Aug 2012

Combination of two stress hormones shuts down brain activity for goal-directed behaviour

Cognition psychologists at the Ruhr-Universit-t together with colleagues from the University Hospital Bergmannsheil (Prof. Dr. Martin Tegenthoff) have discovered why stressed persons are more likely to lapse back into habits than to behave goal-directed. The team of PD Dr. Lars Schwabe and Prof. Dr. Oliver Wolf from the Institute for Cognitive Neuroscience have mimicked a stress situation in the body using drugs.

26 Jul 2012